Accessibility Menu
Cosciens Biopharma logo

Cosciens Biopharma(TSX) AEZS

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1995)-100%
5 Year-97%
1 Year-43%
1 Month-1%
N/A
Cosciens Biopharma last closing stock price
MetricPriceDate
Last closeCAD 7.882026-08-14
Cosciens Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+11.77%CAD 7.052026-08-06
1 month-1.13%CAD 7.972026-07-15
3 month+5.91%CAD 7.442026-05-15
Year to date-7.51%CAD 8.522025-12-31
1 year-43.27%CAD 13.892025-08-14
3 year-82.94%CAD 46.202023-08-15
5 year-96.95%CAD 258.002021-08-13
Since inception-100%CAD 420,810.131995-12-19

Cosciens Biopharma Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.47M

Net Income (TTM)

-$5.24M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 13, 2024

AEZS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cosciens Biopharma

Aeterna Zentaris Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutic drugs and diagnostic tests. Established in 1990 and based in Summerville, South Carolina, the company is known for its flagship product, Macrilen, which is used for diagnosing growth hormone deficiency.

Products and Services
  • Macrilen, a diagnostic tool for growth hormone deficiency
  • COVID-19 vaccine development in collaboration with the University Wuerzburg
  • Research on treatments for neuromyelitis optica spectrum disorder and Parkinson's disease
Growth Outlook
  • Partnerships with leading institutions enhance research capabilities
  • Ongoing investigations into oncology applications for Macrilen
  • Potential expansion into new therapeutic areas through strategic licensing
Financial Highlights
  • Q2 2024 revenue of $2.34 million, a significant increase from previous quarters
  • Cash and cash equivalents of $27.8 million as of June 30, 2024
  • Current ratio of 5.57 indicates strong liquidity position
Aeterna Zentaris Inc. operates in a dynamic biotechnology sector, leveraging its innovative products and strategic partnerships to drive growth. The company’s focus on research and development, particularly in the areas of growth hormone deficiency and oncology, positions it well for future opportunities. Recent financial performance shows promising revenue growth and a solid liquidity position, which may attract potential investors looking for opportunities in the biopharmaceutical space. The ongoing collaborations and product developments further enhance the company's potential for long-term success.
AI Generated • Aug 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Peter Harry Puccetti, CFA

Website

www.cosciensbio.com

Headquarters

Summerville, SC 29486, US

AEZS Financials

Key Financial Metrics (TTM)

Gross Margin

37.98%

Operating Margin

-99.15%

Net Income Margin

-92.11%

Return on Equity

-92.59%

Return on Capital

-83.42%

Return on Assets

-38.42%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$865.00K

Operating Income

-$20.81M

EBITDA

-$12.25M

Operating Cash Flow

-$14.44M

Capital Expenditure

-$176.00K

Free Cash Flow

-$14.62M

Cash & ST Invst.

$27.80M

Total Debt

$1.69M

Cosciens Biopharma Performance Analysis

Cosciens Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 7,342,45411.3%
20232023-12-31USD 9,640,81431.3%
20242024-12-31USD 13,133,82236.2%
20252025-12-31USD 10,476,870-20.2%
Cosciens Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30-99.9%
Q42023-12-313933.3%
Q12024-03-31-96.7%
Q22024-06-3058325.0%
Cosciens Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -73.12167.0%
20232023-12-31USD -30.56-58.2%
20242024-12-31USD -24.37-20.2%
20252025-12-31USD -13.72-43.7%
Cosciens Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-3040.4%
Q42023-12-31-267.7%
Q12024-03-3144.7%
Q22024-06-3025.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$2.34M

+4.1%

Gross Profit

$819.00K

-61.1%

Gross Margin

35.04%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

12

N/A

Net Income

-$1.42M

+43.5%

EBITDA

-$3.27M

-361.1%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$27.80M

-34.1%

Total Debt

$1.69M

+633.5%

Accounts Receivable

$1.36M

+9.5%

Inventory

$3.06M

+3184.9%

Long Term Debt

$1.28M

-58.7%

Short Term Debt

$407.00K

-30.2%

Return on Assets

-38.42%

N/A

Return on Invested Capital

-45.42%

N/A

Free Cash Flow

-$1.55M

+64.0%

Operating Cash Flow

-$1.39M

+67.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
THNK.VThink Research Corporation
CA$0.32+1.61%
IGX.TOIntelGenx Technologies Corp.
CA$0.24+17.07%
IMV.TOIMV Inc.
CA$1.12+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About AEZS

What is the current price of Cosciens Biopharma?

Cosciens Biopharma is trading at N/A per share.

What is the 52-week range for Cosciens Biopharma?

Over the past 52 weeks, Cosciens Biopharma has traded between N/A and N/A.

How much debt does Cosciens Biopharma have?

As of the most recent reporting period, Cosciens Biopharma reported total debt of $2.78M.

How much cash does Cosciens Biopharma have on hand?

Cosciens Biopharma reported $7.49M in cash and cash equivalents in its most recent financial results.

What is Cosciens Biopharma’s dividend yield?

Cosciens Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services